Circumventing Pediatric Solid Tumor Microenvironment Resistance by Combinatorial CAR NK and Immunomodulating Therapy |
New York Medical College / Mitchell Cairo, MD |
Reach Grants |
2023 |
New York |
Feasibility Study of Dual Inhibition of MDM2 and Tubulin in Treatment of AML |
Emory University / Muxiang Zhou, MD |
Reach Grants |
2023 |
Georgia |
Therapeutic Targeting of PGBD5-induced DNA Repair Dependency in Pediatric Solid Tumors |
Memorial Sloan-Kettering Cancer Center / Alex Kentsis, MD/PhD |
Reach Grants |
2017 |
New York |
Immuno-therapeutic Targeting of CD56 in CBA2T3/GLIS2-AML in Children |
Fred Hutchinson Cancer Research Center / Soheil Meshinchi, MD/PhD |
Reach Grants |
2018 |
Washington |
Stroma Biology Identifies Heparin as a Differentiating Agent in Neuroblastoma
|
Duke University Medical Center / Gerard Blobe, MD, PhD |
Reach Grants |
2013 |
North Carolina |
Neural Stem Cell-Mediated Drug Delivery for Targeted Treatment of Medulloblastoma
|
Beckman Research Institute of City of Hope / Margarita Gutova, MD |
Reach Grants |
2013 |
California |
Astatine-211 Meta-Astatobenzylguanidine ([211At]MABG) Targeted Radiotherapy for Disseminated Neuroblastoma |
Children’s Hospital of Philadelphia / John Maris, MD |
Reach Grants |
2016 |
Pennsylvania |
Moving EphB4 Therapeutics to Pediatric Phase I/II Trials |
Oregon Health & Science University / Charles Keller, MD |
Reach Grants |
2013 |
Oregon |
Targeting PLK1 as a Common Mechanism in Ph-like ALL |
University of Texas M.D. Anderson Cancer Center / Joya Chandra, PhD |
Reach Grants |
2016 |
Texas |
Combining Oncolytic Vaccinia Virus with GD2.CAR-modified Vaccinia Virus-specific T-cells for the Treatment of Relapsed Neuroblastoma and Sarcoma |
Baylor College of Medicine / Cliona Rooney, PhD |
Reach Grants |
2013 |
Texas |